ArticlePloS one2018
Characterization of the Mel1c melatoninergic receptor in platypus (Ornithorhynchus anatinus).
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 29 citations in OpenAlex.
- Melatonin rhythms beyond the pineal organ: gene expression of receptors and biosynthesis enzymes in wild and F1 Senegalese sole.Fish physiology and biochemistry · 2025Article
- Why Are We Still Cloning Melatonin Receptors? A Commentary.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Alternative Ligands at Melatonin Receptors.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Measuring Binding at the Putative Melatonin Receptor MT3.Methods in molecular biology (Clifton, N.J.) · 2022Article
- GPR50-Ctail cleavage and nuclear translocation: a new signal transduction mode for G protein-coupled receptors.Cellular and molecular life sciences : CMLS · 2020Article
- The five dimensions of receptor pharmacology exemplified by melatonin receptors: An opinion.Pharmacology research & perspectives · 2020Review
- Characterization of the various functional pathways elicited by synthetic agonists or antagonists at the melatonin MTPharmacology research & perspectives · 2020Article
- New Insights Into the Evolutionary History of Melatonin Receptors in Vertebrates, With Particular Focus on Teleosts.Frontiers in endocrinology · 2020Review
- Melatonin Target Proteins: Too Many or Not Enough?Frontiers in endocrinology · 2019Review
- Gene expression profiling during hibernation in the European hamster.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melatonin is a neurohormone produced in both animals and plants. It binds at least three G-protein-coupled receptors: MT1 and MT2, and Mel1cGPR. Mammalian GPR50 evolved from the reptilian/avian Mel1c and lost its capacity to bind melatonin in all the therian mammal species that have been tested. In order to determine if binding is lost in the oldest surviving mammalian lineage of monotremes we investigated whether the melatonin receptor has the ability to bind melatonin in the platypus (Ornithorhynchus anatinus), and evaluated its pharmacological profile. Sequence and phylogenetic analysis showed that platypus has in fact retained the ancestral Mel1c and has the capacity to bind melatonin similar to other mammalian melatonin receptors (MT1 and MT2), with an affinity in the 1 nM range. We also investigated the binding of a set of melatoninergic ligands used previously to characterize the molecular pharmacology of the melatonin receptors from sheep, rats, mice, and humans and found that the general profiles of these compounds make Mel1c resemble human MT1 more than MT2. This work shows that the loss of GPR50 binding evolved after the divergence of monotremes less than 190MYA in therian mammals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.